Keyword: Seattle Genetics
Amgen pays $2.7 billion for a 20.5% stake in BeiGene. AstraZeneca tightens its ties to China as China approves a controversial Alzheimer's drug.
Sanofi slims down in Japan. We examine Big Pharma CEOs' Chinese names. Positive data came out from Astellas, Eisai and Chi-Med at ESMO.
If Seattle Genetics' second-quarter earnings report is any indication, the company's lead product is finally living up to its potential.
In one ASCO surprise, the usual complaints about "too much advertising" were absent this year. In fact, attendees mostly shrugged.
The cancer world flocked to this weekend's ASCO meeting, traditionally the biggest oncology confab of the year. Here's your need-to-know.
Gearing up for the year's largest cancer confab, we break down the highlights to give you a glimpse of the studies we’re tracking, so you can follow along, too.
Now well on its way to becoming a multiproduct company, Seattle Genetics has decided the time is right to bring in its first chief commercial officer.
Every line item in Seattle Genetics CEO Clay Siegall’s 2018 pay package increased, leading to a total of $18.1 million, versus $8.6 million in 2017.
As spring rolls on each year, proxy filings pile up, disclosing executive pay for the prior year. And as in past years, FiercePharma has tracked the info to present the top CEO pay packages in biopharma, ranging from nearly $60 million in 2018 down to $16 million.
Clay Siegall's equity awards skyrocketed to $15.8 million last year from $6.8 million in 2017, pushing his total higher than many a CEO's pay.